Daily Stock Analysis, AQ, APTEVO THERAPEUTICS INC. - COMMON STOCK WHEN ISSUED, priceseries

APTEVO THERAPEUTICS INC. - COMMON STOCK WHEN ISSUED. Daily Stock Analysis
Stock Information
Open
9.79
Close
9.57
High
9.81
Low
9.54
Previous Close
9.81
Daily Price Gain
-0.24
YTD High
10.00
YTD High Date
Apr 17, 2019
YTD Low
7.21
YTD Low Date
Feb 13, 2019
YTD Price Change
0.83
YTD Gain
9.50%
52 Week High
15.38
52 Week High Date
Apr 20, 2018
52 Week Low
7.08
52 Week Low Date
Oct 26, 2018
52 Week Price Change
-5.18
52 Week Gain
-35.12%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 25. 2019
8.51
Apr 9. 2019
8.94
11 Trading Days
5.02%
Link
Company Information
Stock Symbol
AQ
Exchange
NASDAQ
Company URL
http://-
Company Phone
206-838-0500
CEO
Marvin L. White
Headquarters
Washington
Business Address
2401 4TH AVE., SUITE 1050, SEATTLE, WA 98121
Sector
-
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001671584
About

Aptevo Therapeutics, Inc. focuses on novel oncology and hematology therapeutics to meaningfully improve patient's lives. It also products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immune-oncology. Aptevo Therapeutics was founded on February 22, 2016 and is headquartered in Seattle, WA.

Description

Aptevo Therapeutics Inc., a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company's marketed products also comprise VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals; and IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates include MOR209/ES414, ES210, ES425, and otlertuzumab used to expand on the utility and effectiveness of therapeutic antibodies; and 5E3 mAb, a monoclonal antibody therapeutic that is in pre-clinical development for Alzheimer's disease. The company was incorporated in 2016 and is based in Seattle, Washington. As of August 01, 2016, Aptevo Therapeutics Inc. operates independently of Emergent BioSolutions, Inc.